Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Asthma
Phase PHASE2
Enrollment 540
Locations 222 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Tozorakimab — The drug will be administered subcutaneously.
  • Drug: Placebo — Placebo will be administered subcutaneously.

Primary Outcomes

  • Annualised rate of severe asthma exacerbations (Over 26 to 52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-26
Completion: 2028-02-28
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Tozorakimab — The drug will be administered subcutaneously.
  • Drug: Placebo — Placebo will be administered subcutaneously.
Study Locations (222 sites)
Research Site, Bakersfield, California 93301 United States
Research Site, Huntington Beach, California 92647 United States
Research Site, La Mesa, California 91942 United States
Research Site, Loma Linda, California 92354 United States
Research Site, Long Beach, California 90815 United States
Research Site, Newport Beach, California 92663 United States
Research Site, San Jose, California 95117 United States
Research Site, Wilmington, Delaware 19805 United States
Research Site, Cutler Bay, Florida 33189 United States
Research Site, Hialeah, Florida 33015 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated written informed consent prior to any study-specific procedures. 2. Adults aged 18-75, inclusive when signing the informed consent. 3. Documented physician-diagnosis of asthma for at least 12 months. 4. Treated with medium or high dose ICS in combination with LABA. 5. Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 . 6. Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal. 7. Documented exacerbation history in the last 12 months and biomarker requirements of: 1. ≥ 2 severe exacerbations OR 2. 1 severe exacerbation and: (i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb 8. Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary. 9. Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test. 10. Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: 1. Completed treatment for respiratory infection with antibiotics in the 4 weeks prior to Visit 1. 2. Clinically significant pulmonary disease other than asthma . 3. Current smokers, former smokers with \>10 pack-years history. 4. Clinically significant aortic stenosis or pulmonary arterial hypertension. 5. Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immune complex disease. 6. Unstable cardiovascular disorders.

Infant RSV Immunity Study

NCT07653347
Recruiting
Conditions Respiratory Synctial Virus, Asthma Child...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (\>6-9 months) in infancy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • RSV antibody response (Post-respiratory season 2027 (May 2027))
  • Asthma symptoms (at age 3 years old)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-15
Completion: 2029-12-01
Eligibility
Age: Up to 6 Months
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of British Columbia
Contact Information
Study Contact:
Pascal Lavoie, MDCM PhD FRCPC
604-875-2135
plavoie@bcchr.ca
Allison Watts, PhD
604-875-2000
awatts@bcchr.ca
Pascal Lavoie, MD PhD
(604) 875-2000
plavoie@bcchr.ca
BC Women's Hospital and Health Centre
Interventions
N/A
Study Locations (1 sites)
BC Women's Hospital and Health Centre, Vancouver, British Columbia V6H 3N1 Canada
Eligibility Criteria
Inclusion Criteria: Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital. Exclusion Criteria: Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \< 35 weeks of gestation, or with chronic medical conditions).
Conditions Asthma, Mild Asthma, Moderate Asthma
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this registry aims is to collect a large number of patients with mild and moderate asthma in a real-word conditions for a perspective observation of epidemiological evolution of the disease in relation to the therapeutic interventions available currently and in the near future.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • A cluster-based, real world, cross-sectional perspective, observational cohort study (through study completion; follow-up procedures will last 10 years from the date of the last patient enrolled)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-05-01
Completion: 2032-11
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Societa Italiana di Pneumologia
Collaborators: Società Italiana di Allergologia, Asma e Immunologia Clinica
Principal Investigators:
  • Fulvio Braido (PRINCIPAL_INVESTIGATOR) - IRCCS Ospedale Policlinico San Martino, Department of Internal Medicine (DiMI), University of Genoa
Contact Information
Study Contact:
Fulvio Braido
+ 393386036913
fulvio.braido@unige.it
Fulvio Braido
+393386036913
fulvio.braido@unige.it
IRCCS Ospedale Policlinico San Martino
Interventions
N/A
Study Locations (1 sites)
IRCCS Ospedale Policlinico San Martino, Genova, 16132 Italy
Eligibility Criteria
Inclusion Criteria: * Adult patients * Asthma diagnosis according GINA 2020 algorithm (Annex 1) * Patients enrolled in other previous or ongoing observational studies Exclusion Criteria: * Severe asthma patients according International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. \[Chung KF et al. European Respiratory Journal Feb 2014, 43 (2) 343-373; DOI: 10.1183/09031936.00202013 (Annex 2)\] * Subjects are excluded from this cohort if they exhibit interstitial lung diseases, pulmonary neoplasms, current lung infections, immunological disorders leading to the use of immunosuppressants or continuous treatment with oral steroids.
Conditions Mild to Moderate Asthma
Phase PHASE1, PHASE2
Enrollment 96
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Phase 1 of this study will consist of 2 parts * Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC). * Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously. Phase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: PRA-216 — biologic
  • Drug: Placebo — matching placebo for PRA-216

Primary Outcomes

  • Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) with a single dose of PRA-216 in healthy volunteers (SAD arm) (Up to Study Day 169)
  • Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) of multiple doses of PRA-216 in healthy volunteers (MAD arm) (up to Study Day 169)
  • Phase 2a: To evaluate the effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in asthma participants (Up to Study Day 57)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-11-04
Completion: 2027-01-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prana Therapies Inc
Contact Information
Study Contact:
Linear site contact
+61 (0)8 6382 5110
enquiries@linear.org.au
Ronald Mak, MD
0289648186
ronaldmak@emeritusresearch.com
Emertitus Research Sydney
Sam Francis, MD
0395096166
samfrancis@emeritusresearch.com
Emeritus Research Camberwell
Interventions
  • Drug: PRA-216 — biologic
  • Drug: Placebo — matching placebo for PRA-216
Study Locations (8 sites)
Emertitus Research Sydney, Botany, New South Wales 2019 Australia
Emeritus Research Camberwell, Camberwell, Victoria 3124 Australia
Monash Health, Clayton, Victoria 3168 Australia
Linear, Joondalup, Western Australia 6027 Australia
Linear, Nedlands, Western Australia 6009 Australia
PCRN Waikato, Nawton, Hamilton, Auckland 3200 New Zealand
Pacific Clinical Research Network-Auckland, Takapuna, Auckland 0622 New Zealand
PCRN Wellington, Ebdentown, Upper Hutt, Auckland 5018 New Zealand
Eligibility Criteria
Phase 1 Inclusion Criteria: * Age 18-65 * Must be in good health with no significant medical history * Willing and able to attend all study visits, comply with study requirements * Able and willing to provide written informed consent Exclusion Criteria: * Evidence of clinically significant condition or disease * Any physical or psychological condition that prohibits study completion * Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent * History of severe allergic reactions or hypersensitivity * Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing Phase 2a Inclusion criteria: * Age 18-65 * Must be in good health with no significant medical history * Willing and able to attend all study visits, comply with study requirements. * Able and willing to provide written informed consent * Documented asthma diagnosis prior for at least 12 months prior to screening. * Symptomatic asthma * Currently receiving maintenance asthma medications Exclusion Criteria: * Evidence of clinically significant condition or disease * Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent * Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing * History of severe allergic reactions or hypersensitivity * Current or former smoker with a smoking history of ≥10 pack-years * Receipt of immunosuppressant therapies or biologic therapy for asthma within 6 months of screening * Other investigational agent(s) within 30 days of dosing
Conditions Depression Disorders, Non-suicidal Self-...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims to determine whether beta-band transcranial alternating current stimulation (tACS) can improve impulse inhibition in adolescents with non-suicidal self-injury (NSSI) and to evaluate its safety. The primary questions it seeks to answer are: * Can beta-band tACS significantly reduce the frequency of self-injury and scores on impulsivity scales in adolescents with NSSI? * What discomfort or medical issues may participants experience during tACS intervention? Researchers will compare beta-band tACS with sham stimulation (a procedure that mimics the real stimulation without delivering effective current) to verify its efficacy. Participants will: * Receive two sessions of either tACS or sham stimulation daily, spaced 4 hours apart, for 7 consecutive days (14 sessions in total). * Undergo scale assessments, behavioral tasks, and eye-tracking tests before and after the intervention. * Record any self-injury episodes and adverse reactions, with continuous monitoring and psychological support provided by a professional team.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Beta-frequency transcranial alternating current stimulation — Active beta-frequency transcranial alternating current stimulation: 20 Hz tACS delivered through a 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak, 100 % intensity, gradually ramped up over 30 s, maintained for 20 min, then ramped down over 30 s; two sessions per day with at least 4 h between sessions, repeated for 7 consecutive days (14 total sessions).
  • Device: sham beta-frequency transcranial alternating current stimulation — Sham transcranial alternating current stimulation: identical 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak current ramped up over 30 s and immediately ramped down to 0 mA, followed by 19.5 min of no stimulation to match the 20-min session duration of active tACS; delivered twice daily (≥4 h apart) for 7 consecutive days (14 total sessions).

Primary Outcomes

  • Adolescent Non-suicidal Self-injury Assessment Questionnaire (ANSAQ) reduction in the frequency of self-injury (Once at baseline (pre-treatment) and once at the end of treatment on Day 8.)
  • UPPS-P Impulsive Behavior Scale (UPPS-P) (Once at baseline (pre-treatment) and once at the end of treatment on Day 8.)
  • Brief Barratt Impulsiveness Scale (BBIS) (Once at baseline (pre-treatment) and once at the end of treatment on Day 8.)
  • Eye movement index-fixation time (Once at baseline (pre-treatment) and once at the end of treatment on Day 8.)
  • Eye movement index-fixation counts (Once at baseline (pre-treatment) and once at the end of treatment on Day 8.)
  • Balloon Analog Risk Task-Total number of Balloon explosions (Once at baseline (pre-treatment) and once at the end of treatment on Day 8.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2026-05-31
Eligibility
Age: 12 Years – 22 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anhui Medical University
Principal Investigators:
  • Lei Zhang, doctor (STUDY_DIRECTOR) - School of Mental Health and Psychological Sciences, Anhui Medical University
Contact Information
Study Contact:
Meiling Wang, bachelor
+86 136 4707 0027
1605280093@qq.com
Lei Zhang, doctor
+86 138 6612 9450
anyipsychology@163.com
School of Mental Health and Psychological Sciences, Anhui Medical University
Interventions
  • Device: Beta-frequency transcranial alternating current stimulation — Active beta-frequency transcranial alternating current stimulation: 20 Hz tACS delivered through a 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak, 100 % intensity, gradually ramped up over 30 s, maintained for 20 min, then ramped down over 30 s; two sessions per day with at least 4 h between sessions, repeated for 7 consecutive days (14 total sessions).
  • Device: sham beta-frequency transcranial alternating current stimulation — Sham transcranial alternating current stimulation: identical 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak current ramped up over 30 s and immediately ramped down to 0 mA, followed by 19.5 min of no stimulation to match the 20-min session duration of active tACS; delivered twice daily (≥4 h apart) for 7 consecutive days (14 total sessions).
Study Locations (1 sites)
School of Mental Health and Psychological Sciences, Anhui Medical University, Hefei, Anhui China
Eligibility Criteria
Inclusion Criteria: * 1\) Meet the proposed diagnostic criteria for non-suicidal self-injury (NSSI) in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with ≥5 documented self-injury episodes and at least one incident within the past month as assessed by the Adolescent Non-Suicidal Self-Injury Assessment Questionnaire (ANSAQ); 2) Aged 12-18 years; 3) Right-handed; 4) Possess formal education experience sufficient to comprehend experimental protocols; 5) Normal or corrected-to-normal binocular visual acuity; 6) Voluntarily participate with legal guardians providing written informed consent. Exclusion Criteria: * 1\) Montreal Cognitive Assessment (MoCA) score \< 26; 2) History of suicide attempt(s); 3) Medical history of epilepsy, brain surgery, intracranial tumors, metal implants in the skull, or clinically significant head trauma; 4) History of substance use disorder, brain injury, severe somatic diseases, psychiatric disorders, or comorbid DSM-5 psychiatric conditions; 5) Prior receipt of transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or repetitive transcranial magnetic stimulation (rTMS) within the past 3 months
Conditions Mental Disorders, Healthy Control
Phase Not Applicable
Enrollment 1899
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids — Patients with mental disorders should take the appropriate medicine as prescribed by the doctor,and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Primary Outcomes

  • cortical morphology (40 minutes)
  • target gene charaacteristics (1 day)
  • scale scores (90 minutes.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-01
Completion: 2027-01
Eligibility
Age: 13 Years – 35 Years
Sex: ALL
Volunteers: true
Enrollment: 1899 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: mingjun Zhong
Contact Information
Study Contact:
Yunzhi Pan
15074818197
panyunzhi@csu.edu.cn
Yunzhi Pan
15074818197
panyunzhi@csu.edu.cn
The Second Xiangya hospital of central south univerity
Interventions
  • Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids — Patients with mental disorders should take the appropriate medicine as prescribed by the doctor,and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Study Locations (1 sites)
The Second Xiangya hospital of central south univerity, Changsha, Hunan 410000 China
Eligibility Criteria
Inclusion Criteria: * Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age) * Course of disease: \<24 months * Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks * No nuclear magnetic contraindications. Exclusion Criteria: * Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence * Have a major physical disease or infectious disease * History of coma and serious neurological disease 4.MRI contraindications.
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 470
Locations 69 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Lumateperone — Lumateperone 42 mg capsules administered orally, once daily
  • Drug: Placebo — Matching capsules administered orally, once daily

Primary Outcomes

  • Montgomery-Asberg Depression Rating Scale (Day 43)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-05-02
Completion: 2027-04-05
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 470 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Intra-Cellular Therapies, Inc.
Principal Investigators:
  • Intra-Cellular Therapies, Inc. Clinical Trial (STUDY_DIRECTOR) - Intra-Cellular Therapies, Inc.
Contact Information
Study Contact:
Study Contact
844-434-4210
Participate-In-This-Study1@its.jnj.com
Interventions
  • Drug: Lumateperone — Lumateperone 42 mg capsules administered orally, once daily
  • Drug: Placebo — Matching capsules administered orally, once daily
Study Locations (69 sites)
University of Alabama at Birmingham, Huntsville, Alabama 35801 United States
CNRI-Los Angeles, LLC, Pico Rivera, California 90660 United States
University of Connecticut Health Center, Farmington, Connecticut 06030 United States
Vertex Clinical Research, Clermont, Florida 34711 United States
New Life Medical Research Center, Inc., Hialeah, Florida 33012 United States
Premier Clinical Research Institute, Miami, Florida 33122 United States
Miami Jewish Health System, Miami, Florida 33137 United States
Interventional Psychiatry of Tampa Bay, Tampa, Florida 33629 United States
The Emory Clinic, Atlanta, Georgia 30329 United States
CenExeli Research LLC, Decatur, Georgia 30030 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or female patients between the ages of 18 and 65 years, inclusive; 2. Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria: 1. The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening; 2. Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline; 3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline; 4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline; 5. Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning. 3. Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration: 1. citalopram/escitalopram 2. fluoxetine 3. paroxetine 4. sertraline 5. duloxetine 6. levomilnacipran/milnacipran (if locally approved for MDD) 7. venlafaxine/desvenlafaxine 8. bupropion 9. vilazodone 10. vortioxetine Exclusion Criteria: 1. Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including: 1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder; 2. Bipolar Disorder; 2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including: 1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment; 2. Eating disorder; 3. Substance use disorders (excluding nicotine); 4. Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status; 5. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment; 3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline; 4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline; 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or: 1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit; 2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening; 3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or 4. The patient is considered to be in imminent danger to him/herself or others. 6. The patient has a first MDE at age 60 years or older.
Conditions Depressive Disorder, Major, Treatment Ou...
Phase Not Applicable
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The BrainDrugs-D study uses multimodal neuroimaging combined with self-report measures, clinical and molecular markers to identify clinically relevant predictors that can identify subtypes of major depressive disorder (MDD) and, in a naturalistic setting, predict treatment response to standard antidepressive treatment. The cohorts are followed in nationwide health registries.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Combination Product: Treatment Package for First-Episode Depression — The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.

Primary Outcomes

  • Clinical remission (Baseline to 6 months after treatment start)
  • Clinical improvement (Baseline to 6 months after treatment start)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-06-15
Completion: 2026-12
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen University Hospital, Rigshospitalet
Collaborators: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital, Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak, Lundbeck Foundation
Principal Investigators:
  • Martin B Jørgensen, DMSc (PRINCIPAL_INVESTIGATOR) - Psychiatric Center Copenhagen
  • Gitte MK Knudsen, DMSc (STUDY_DIRECTOR) - Neurobiology Research Unit, Rigshospitalet
Contact Information
Study Contact:
Kristian HR Jensen, MD
+45 35456720
kristian.reveles.jensen@nru.dk
Martin B Jørgensen, DMSc
+45 38647082
Martin.Balslev.Joergensen@regionh.dk
Gitte M Knudsen, Professor
+45 3545 6712
gitte@nru.dk
Neurobiology Research Unit, Rigshospitalet
Interventions
  • Combination Product: Treatment Package for First-Episode Depression — The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
Study Locations (1 sites)
Neurobiology Research Unit, Rigshospitalet, Copenhagen, 2100 Denmark
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 65 years * Fulfilment of International Classification of Diseases version 10 diagnostic criteria for a primary depressive episode (i.e., not secondary to known organic or other psychiatric disorder). * Referral to a treatment package for single-episode depression. Exclusion Criteria: * Psychosis or psychotic symptoms * History of severe head trauma * Somatic disease associated with morphological brain changes (e.g., brain tumour) * Insufficient Danish language skills to complete questionnaires and cognitive testing Additional exclusion criteria for Cohort II: * Severe somatic disease * Contraindications for MRI (e.g., metal implants, claustrophobia or back problems) Additional exclusion criteria for Cohort III: * Severe somatic disease * Contraindications for MRI * Exposure to radioactivity \>10 mSv within the last year * Pregnancy or breastfeeding * Use of psychotropic drugs
Conditions Depression, Depressive Disorder, Treatme...
Phase PHASE2
Enrollment 180
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomised, placebo-controlled, parallel-group trial comparing OSU6162 at flexible dosage with placebo as add-on to treatment with an SSRI/SNRI in patients with depression that have not responded to treatment with an SSRI/SNRI per se for at least 6 weeks. The study will last for 6 weeks, after which those not having responded will leave the trial and those having responded will be offered to continue treatment without unblinding for another 4 weeks. Optional Substudy 1 and 2: Baseline and treatment-associated change in reward-related striatal activity per fMRI-assessment. (Substudy 1). Brain signal variability per fMRI-assessment. (Substudy 1). Probabilistic Reward Task (PRT). (Substudy 2). While assessment of the efficacy and safety of OSU6162 is the main objective of this study, possible differences between the two treatment groups with respect to a number of biomarkers in serum will also be explored. Multicenter trial: Multiple sites four Gothenburg, Lund, Stockholm and Uppsala.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: OSU6162 — OSU6162
  • Drug: Placebo — Placebo

Primary Outcomes

  • Bech 6-item subscale of the Hamilton Depression Rating Scale (HDRS) (Endpoint at 42 days treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-04-21
Completion: 2029-12-31
Eligibility
Age: 25 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Göteborg University
Collaborators: Arvid Carlsson Research AB
Principal Investigators:
  • Elias Eriksson, Professor (STUDY_DIRECTOR) - Göteborg University
Contact Information
Study Contact:
Elias Eriksson, Professor
+46 709 555055
elias.eriksson@neuro.gu.se
Jakob Näslund, MD, PhD
+46 702 947960
jakob.naslund@vgregion.se
Daniel Lindqvist, MD, PhD
daniel.lindqvist@med.lu.se
Skåne University Hospital Psychiatry Lund
Interventions
  • Drug: OSU6162 — OSU6162
  • Drug: Placebo — Placebo
Study Locations (4 sites)
Skåne University Hospital Psychiatry Lund, Lund, Skåne County 222 40 Sweden
North Stockholm psychiatry Stockholm region, Stockholm, Stockholm County 11321 Sweden
Uppsala University Hospital Department of neuroscience, Uppsala, Uppsala County 75185 Sweden
Sahlgrenska University Hospital, Gothenburg, Västra Götaland County Sweden
Eligibility Criteria
Inclusion Criteria In order to be included in the study, subjects must meet the following criteria: 1. Signed informed consent. 2. Age: 25-75 on the day of screening. 3. Meeting DSM-5 criteria for major depressive disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI). 4. A symptom-free period preceding the current episode within the past two years confirmed at interview. 5. Not significantly improved, as judged by both doctor and patient, after having been treated with one of the following SSRIs/SNRIs: citalopram, escitalopram, paroxetine, sertraline, fluoxetine, duloxetine, or venlafaxine for at least 6 weeks. 6. Displaying a sum score of MADRS ≥22. 7. In women of childbearing potential (WOCBP): negative result of a pregnancy test and a method of contraception with a failure rate of less than 1 %. Contraception must be used during the treatment and follow-up period. Acceptable forms of contraception are: 1. Use of combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation * oral * intravaginal * transdermal 2. progestogen-only hormonal contraception associated with inhibition of ovulation: * oral * injectable * implantable 3. Placement of intrauterine device (IUD) or intrauterine hormone releasing system (IUS) 4. Bilateral tubal occlusion or ligation 5. Vasectomised partner (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate and provided that male partner is the sole sexual partner of the WOCBP trial participant). 6. Sexual abstinence. 8. Male patients must agree to use condoms during the study and for 2 weeks after the end of the study/last dose of IMP, unless their partner is using a highly efficient method of contraception, as described above. Exclusion criteria Subjects must not be included in the study if any of the following criteria are met: 1. Meeting MINI criteria at interview for suicidality, manic episode, hypomanic episode, bipolar I, bipolar II, bipolar unspecified, bipolar I with psychotic symptoms, panic disorder (current), agoraphobia, posttraumatic stress disorder, alcohol dependency, alcohol abuse, substance dependency (non-alcoholic), substance abuse (non-alcoholic), psychotic disorders, mood disorders with psychotic features, anorexia nervosa, bulimia nervosa, anorexia nervosa binge eating / purging type, or antisocial personality disorder. Meeting MINI criteria at interview for generalised anxiety disorder, obsessive compulsive disorder or social anxiety (social phobia), unless the present symptoms can predominantly be attributed to a diagnosis of major depressive disorder. 2. A history of substance/alcohol abuse within 2 years prior to screening. 3. A previous diagnosis of a personality disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, or intellectual disability. 4. Any other previously diagnosed or suspected CNS disorder that according to the investigator renders the patient unsuitable for participation in the trial. 5. Any factor that according to the investigator renders it unlikely that the patient will comply with the instructions regarding treatment, visits, refraining from use of central stimulants etc. 6. Any somatic illness that according to the investigator renders the patient unsuitable for participation in the trial. 7. Any signs or symptoms of somatic illness resulting from assessment of vital signs, physical examination, clinical laboratory tests, and 12-lead ECG that according to the investigator renders the patient unsuitable for participation for safety reasons, including a QTc-time on ECG exceeding 450 ms in men and 460 ms in women. 8. Any change in dosage of said SSRI/SNRI within 4 weeks prior to screening or at any time during the course of the trial. 9. Treatment with any other psychoactive drug than said SSRI/SNRI with the exception of using mirtazapine up to 15 mg for sleep, occasional use of benzodiazepines and benzodiazepine-like anxiolytics or hypnotics and occasional use of antihistaminergic sedatives (without anti-dopaminergic effects) within 4 weeks prior to screening and at any time during the course of the trial. 10. Patients who are receiving concomitant therapy with potent cytochrome P450 enzyme inhibitors (e.g., bupropion, fluvoxamin, ketoconazole, itraconazole, telithromycin, clarithromycin, protease inhibitors, quinidine, and terbinafine). 11. Ongoing treatment with drugs with a narrow therapeutic window where either lower or higher serum levels are potentially harmful (including but not limited to warfarin along with other anticoagulants, digoxin along with other antiarrythmics, anticonvulsants prescribed for treatment of epilepsy, cyclosporine, immunosuppressants, and lithium). 12. Current treatment with any prescribed or OTC drug that according to the investigator renders the subject unsuitable for participation in the trial. 13. Previous intake of OSU6162. 14. Current participation in another clinical trial. 15. Nursing women. 16. Substudy only: Relative and/or absolute contraindications to lumbar puncture and functional Magnetic Resonance Imaging (fMRI), as per clinical practice. This includes ongoing treatment with anticoagulants such as NOAC or warfarin.
Conditions Anxiety, Depression, Psychological Distr...
Phase NA
Enrollment 518
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this cluster randomized controlled trial is to explore if mental health in Dutch small and medium-sized enterprises (SMEs) can be improved by the World Health Organization's online program Doing What Matters in Times of Stress (DWM). The main questions it aims to answer are: * Does DWM improve the mental health of employees working in Dutch SMEs? * Does DWM improve work-related outcomes in employees working in Dutch SMEs? * How can DWM be implemented at a large scale in Dutch SMEs? Researchers will compare two groups to see if the DWM program is effective. One group will receive the DWM program and Care-as-Usual (group 1), and the other group will receive Care-as-Usual only (group 2). Participants will: * Follow the online DWM program for 5 weeks (only group 1). * Take part in 6 telephone appointments with a facilitator (helper) that provides extra support to complete the program (only group 1). * Complete 3 sets of questionnaires. Each set of questionnaire takes about 15 minutes to be completed (group 1 and group 2).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Doing What Matters in Times of Stress — DWM is the illustrated guide of the original stress management intervention - Self-Help Plus and can be offered online through a web-based application. DWM is a low-intensity and transdiagnostic intervention that has been designed to be widely applicable to a variety of mental health problems (depression, anxiety and PTSD). DWM is based on acceptance and commitment therapy (ACT), a modern form (third wave) of cognitive-behavioural therapy with a strong focus on mindfulness practices and identification of values, with exercises which aim to reduce distress and build social support, adaptive coping and resilience. DWM includes five modules, each of which focuses on a specific skill. The online version of DWM has been designed to release a module every week, so the program is finalized in 5 weeks. In this trial, participants will receive the guided version of DWM: participants will have a short (15 minutes) weekly support call with a helper (6 calls in total).

Primary Outcomes

  • Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS) (Change from Baseline (week 1) to 1-week post intervention (week 7))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-19
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 518 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VU University of Amsterdam
Collaborators: World Health Organization, University of Copenhagen, University Hospital Heidelberg
Principal Investigators:
  • Marit E. Sijbrandij (PRINCIPAL_INVESTIGATOR) - VU University of Amsterdam
Contact Information
Study Contact:
Cătălin Gherdan
+31 20 59 82587
c.gherdan@vu.nl
Anke B. Witteveen
a.b.witteveen@vu.nl
Cătălin Gherdan
+31 20 59 82587
c.gherdan@vu.nl
Vrije Universiteit Amsterdam
Interventions
  • Behavioral: Doing What Matters in Times of Stress — DWM is the illustrated guide of the original stress management intervention - Self-Help Plus and can be offered online through a web-based application. DWM is a low-intensity and transdiagnostic intervention that has been designed to be widely applicable to a variety of mental health problems (depression, anxiety and PTSD). DWM is based on acceptance and commitment therapy (ACT), a modern form (third wave) of cognitive-behavioural therapy with a strong focus on mindfulness practices and identification of values, with exercises which aim to reduce distress and build social support, adaptive coping and resilience. DWM includes five modules, each of which focuses on a specific skill. The online version of DWM has been designed to release a module every week, so the program is finalized in 5 weeks. In this trial, participants will receive the guided version of DWM: participants will have a short (15 minutes) weekly support call with a helper (6 calls in total).
Study Locations (1 sites)
Vrije Universiteit Amsterdam, Amsterdam, North Holland 1081 HV Netherlands
Eligibility Criteria
Inclusion Criteria (SMEs): * Having 10 to 250 employees * Being located in the Netherlands In case of insufficient recruitment among SMEs, a mitigation strategy is to recruit public and non-profit organizations, and units of larger organizations, all employing between 10 and 250 employees. Inclusion Criteria (Individual participants): * 18 years or older * Having elevated levels of psychological distress (Kessler Psychological Distress Scale; K10 scores \> 15.9) * Sufficient literacy and mastery (written and spoken) of one of the languages the DWM intervention is being delivered in (i.e., Dutch or English) * Having access to an electronic device with internet access to follow the intervention * Written informed consent before entering the study Exclusion Criteria (Individual participants): * Imminent suicide risk, or expressed acute needs or protection risks that require immediate follow-up * Currently receiving specialized psychological treatment (e.g., EMDR or CBT) at the time of screening * In case of current psychotropic medication use: being on an unstable dose for at least 2 months or a change in dosage over the past 2 months. * Having participated in the preceding ASCEND trial as supervisor (see NCT ID: NCT06989398)
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: NMDAE — Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
  • Drug: Placebo Cap — Use of placebo as a comparator

Primary Outcomes

  • Change in Hamilton Rating Scale for Depression (week 0, 2, 4, 6, 8)
  • Change in Global Assessment of Functioning (Week 0, 2, 4, 6, 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-01-25
Completion: 2026-12
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China Medical University Hospital
Contact Information
Study Contact:
Hsien-Yuan Lane, M.D., Ph.D
886 4 22052121
hylane@gmail.com
Hsien-Yuan Lane, M.D., Ph.D
886 4 22052121
hylane@gmail.com
Department of Psychiatry, China Medical University Hospital
Interventions
  • Drug: NMDAE — Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
  • Drug: Placebo Cap — Use of placebo as a comparator
Study Locations (1 sites)
Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Eligibility Criteria
Inclusion Criteria: * Have a DSM-5 (American Psychiatric Association) diagnosis of MDD * Have failed to respond to at least one antidepressant with adequate dosage and treatment duration * Their original treatments should have been unchanged for at least 8 weeks. Some treatment-resistant patients (that is, having failed to respond to at least two different classes of antidepressants) who have started to refuse any antidepressant by themselves due to previous failure experience are also allowed, if they have already been antidepressant-free for at least 2 weeks * 17-item Hamilton Rating Scale for Depression total score ≥ 18 * Agree to participate in the study and provide informed consent Exclusion Criteria: * Current substance abuse or history of substance dependence in the past 6 months * History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study * Bipolar disorder, schizophrenia or other psychotic disorder * Moderate-severe suicidal risks * Severe cognitive impairment * Initiating or stopping formal psychotherapy within six weeks prior to enrollment * A history of previously received electroconvulsive therapy * Inability to follow protocol
Conditions Anxiety Disorders and Symptoms, Depressi...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare the effectiveness of a standard mobile cognitive behavioral therapy program to a personalized mobile cognitive behavioral therapy program that introduces new skills over a shorter period of time. Participants will use the Maya app for two days per week, at least 20 minutes per day, for six weeks. Assessments will include a weekly check in with a member of the research team, questionnaires, and optional electroencephalographic (EEG) recordings at the beginning and end of the 6-week intervention. The investigators think that that the less burdensome personalized program will be just as effective at improving symptoms of anxiety and depression as the general program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Personalized MAYA Mobile App — All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
  • Behavioral: General MAYA Mobile App — New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.

Primary Outcomes

  • Change in anxiety symptoms from pre-intervention to post-intervention as measured by the HAM-A. (Baseline to endpoint [Week 6])
  • Change in depressive symptoms from pre-intervention to post-intervention as measured by HAM-D. (Baseline to endpoint [Week 6])
  • Change in anxiety symptoms from pre-intervention to post-intervention as measured by the anxiety subscale of the DASS. (Baseline to endpoint [Week 6])
  • Change in depressive symptoms from pre-intervention to post-intervention as measured by the depression subscale of the DASS. (Baseline to endpoint [Week 6])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-02
Completion: 2027-07
Eligibility
Age: 18 Years – 25 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Children's Health Fund
Principal Investigators:
  • Jennifer Bress, Ph.D. (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Maddy Schier
(646) 289-5271
mas4019@med.cornell.edu
Zareen Mir
(646)-289-5271
zam4005@med.cornell.edu
Jennifer Bress, Ph.D
914.997.8683
jeb2061@med.cornell.edu
Weill Cornell Medical College
Interventions
  • Behavioral: Personalized MAYA Mobile App — All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
  • Behavioral: General MAYA Mobile App — New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
Study Locations (1 sites)
Weill Cornell Medical College, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 25 years. * Primary diagnosis of an anxiety, depressive, or bipolar disorder as determined by a score of 4 or greater on the Clinical Severity Rating of the Anxiety Disorders Interview Schedule (ADIS). * If an individual is diagnosed with bipolar disorder, they must be currently euthymic or experiencing a depressive episode. * Access to an Apple iPhone, iPad, or Android device. Exclusion Criteria: * History of neurologic disorder that may affect the neural systems of interest or participant's ability to participate * Lifetime diagnosis of a psychotic disorder. * Current hypomanic or manic episode. * Currently in cognitive behavior therapy. * Change in dose of a psychiatric medication in the past 12 weeks. * Initiation of psychotherapy in the past 12 weeks. * Intent or plan to attempt suicide.